Compare GEVO & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEVO | ENGN |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.1M | 605.5M |
| IPO Year | 2011 | N/A |
| Metric | GEVO | ENGN |
|---|---|---|
| Price | $2.00 | $9.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $6.42 | ★ $22.71 |
| AVG Volume (30 Days) | ★ 2.6M | 240.3K |
| Earning Date | 03-05-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $120,932,000.00 | N/A |
| Revenue This Year | $913.54 | N/A |
| Revenue Next Year | $11.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 675.75 | N/A |
| 52 Week Low | $0.92 | $2.65 |
| 52 Week High | $2.95 | $11.14 |
| Indicator | GEVO | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 54.33 |
| Support Level | $1.94 | $8.16 |
| Resistance Level | $2.12 | $9.20 |
| Average True Range (ATR) | 0.08 | 0.63 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 20.26 | 59.87 |
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.